This study demonstrated a manageable safety profile and exhibited substantial antitumor activity in newly diagnosed patients with CD30-positive PTCL [22]. The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.